Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Ville Vartiainen, Janne Raula, Luis M. Bimbo, Jenni Viinamäki, Janne T. Backman, Nurcin Ugur, Esko Kauppinen, Eva Sutinen, Emmi Joensuu, Katri Koli, Marjukka Myllärniemi

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalInternational Journal of Pharmaceutics
Volume544
Issue number1
Pages (from-to)121-128
Number of pages8
ISSN0378-5173
DOIs
Publication statusPublished - 10 Jun 2018
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 317 Pharmacy
  • 3121 Internal medicine
  • Idiopathic pulmonary fibrosis
  • Antifibrotics
  • Tilorone
  • Dry powder inhaler
  • AQUEOUS-SOLUTIONS
  • N-ACETYLCYSTEINE
  • PROLIFERATION
  • MODEL
  • DELIVERY
  • L-LEUCINE
  • IN-VITRO CHARACTERIZATION
  • SALBUTAMOL SULFATE
  • GAS-PHASE
  • WORLD EXPERIENCES PIRFENIDONE

Cite this